1. Scrip

Kintor Soars On COVID Antiviral Data But Results' Significance Still Unclear

 
• By Dexter Jie Yan

Chinese firm Kintor disclosed findings from a pivotal Phase III trial showing its androgen receptor antagonist proxalutamide achieved a 50% reduction in risk of hospitalization or death in COVID-19 patients with mild-to-moderate infection, although uncertainty remains over it being “unable to provide” a p-value in some data analyses.

China oral antiviral
proxalutamide among China's first oral antiviral candidates for COVID-19 • Source: Alamy

Hong Kong-listed Kintor Pharmaceutical Ltd. on 6 April released top-line results from a placebo-controlled, pivotal clinical trial to study its oral COVID-19 antiviral proxalutamide, marking one of the first attempts by a Chinese firm to investigate such a candidate in an international Phase III study.

A repurposed androgen receptor-targeting prostate cancer drug, proxalutamide was studied in 733 non-hospitalized patients enrolled from April to December 2021, and the trial also included participants who had been vaccinated against COVID-19

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia